Ashwagandha Withania somnifera (L.) Dunal
Also called: Indian ginseng
Ashwagandha is an evergreen shrub found in parts of India, Africa and the Middle East, used for thousands of years in Ayurvedic medicine. Supplements typically contain root, leaf, or root-and-leaf extracts; most commercial products use root extract.
- Category
- Botanical
- Part used
- Root (some products use root and leaf)
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2022 meta-analysis (Phytother Res) pooled 12 RCTs (1,002 participants) of ashwagandha extract versus placebo for anxiety and stress; the authors rated the certainty of evidence as low. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBrain, mood and sleep3 topics
CSeveral areas, whole body or blood1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Stress and cortisol in adults | B | A 2021 systematic review of seven trials (491 adults, all in India, 6 to 8 weeks) found lower stress, anxiety and serum cortisol than placebo; one 12-week trial of 120 adults found no effect on perceived stress. [2] |
| Anxiety | C | NCCIH describes the evidence on anxiety as unclear. [1] |
| Sleep | B | A 2021 meta-analysis of five placebo-controlled trials (400 participants) found a small but significant effect on overall sleep (SMD −0.59, 95% CI −0.75 to −0.42), more prominent in adults with insomnia, at 600 mg/day or more and over 8 weeks or longer. [5] |
| Testosterone and sperm quality in men | C | NCCIH describes some limited evidence that 2 to 4 months of use may increase testosterone levels and sperm quality. [1] |
| Athletic performance, cognition, diabetes, menopause and other uses | C | NCCIH states there isn't enough evidence to determine whether ashwagandha helps these or other conditions, including COVID-19. [1] |
Main constituents: Withanolides (steroidal lactones) and alkaloids; root and leaf differ in chemical composition [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Trials in the 2021 stress review used 240 to 1,250 mg/day of extract or 12,000 mg/day of whole root granules for 6 to 8 weeks; benefits appeared greater at 500 to 600 mg/day. [2]
- Products are sold in concentrations of 150 to 600 mg, taken one to three times daily; total daily dose varies widely. [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score BABCDEA: well known causeE: unlikely cause
LiverTox likelihood score B: likely cause of clinically apparent liver injury (chapter last updated December 3, 2024).
Details and sources - Pregnancy and breastfeedingNCCIH: ashwagandha should be avoided during pregnancy and not used while breastfeeding.
2 statements in the profile.
Details and sources - Interactions with medicines3 listed
Diabetes and blood pressure medicines; Immunosuppressants, sedatives and anticonvulsants; Thyroid hormone medicines
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada, Ashwagandha monograph (February 28, 2025), adults 18 and older: 2-6 g dried root per day (traditional Ayurvedic claims) …
Details and sources
- May be safe in the short term (up to 3 months); long-term safety is not known. [1]
- Possible drowsiness, stomach upset, diarrhea and vomiting. [1]
- Liver injury is rare but reported. LiverTox likelihood score B (likely cause of clinically apparent liver injury); onset 2 to 12 weeks after starting, usually cholestatic or mixed, with jaundice and itching; most cases mild to moderate and self-limited. [3]
- Three case reports describe thyrotoxicosis that resolved after stopping ashwagandha. [2]
- Should be avoided during pregnancy and not used while breastfeeding. Not recommended before surgery or for people with autoimmune or thyroid disorders. [1]
- Because it may increase testosterone, people with hormone-sensitive prostate cancer should avoid it. [1]
Interactions
| With | What happens |
|---|---|
| Diabetes and blood pressure medicines | Evidence suggests ashwagandha might interact with these medicines. [1] |
| Immunosuppressants, sedatives and anticonvulsants | Listed by NCCIH among medicines ashwagandha might interact with. [1] |
| Thyroid hormone medicines | Listed by NCCIH as a possible interaction. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- Denmark banned the use of ashwagandha in 2023 after a 2020 risk assessment; France's ANSES (2024) recommended against use in certain groups, including pregnant and breastfeeding women and people with endocrine disorders. [2]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Withanolides (LiverTox: the ingredient responsible for activities and side effects is not known, but withanolides are suspected) Steroidal lactones [P3]
- Withaferin A, a withanolide found at much higher relative concentrations in leaves (typically more than 100 times) and stems (typically more than 10 times) than in roots Withanolide (steroidal lactone) [P4]
- Alkaloids; root and leaf differ in chemical composition Alkaloids [P2]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming Withania somnifera (NDI 1180, submitted 2020-09-10). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P6]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox likelihood score B: likely cause of clinically apparent liver injury (chapter last updated December 3, 2024). Onset is 2 to 12 weeks after starting, usually cholestatic or mixed, with jaundice and itching; most cases are mild to moderate and self-limited. [P3]
Interactions with medicines
- Diabetes and blood pressure medicines: NCCIH: evidence suggests ashwagandha might interact with these medicines. [P1]
- Immunosuppressants, sedatives and anticonvulsants: Listed by NCCIH among medicines ashwagandha might interact with. [P1]
- Thyroid hormone medicines: Listed by NCCIH as a possible interaction. [P1]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- BAPP bulletin 'Adulteration of ashwagandha (Withania somnifera) roots and extracts' (2018): the known adulterant is undisclosed non-root parts of the same plant (leaves, stems, aerial parts), which are rich in withaferin A. In one study, 8 of 10 commercial extracts labeled as root-derived (80%) contained flavonol glycoside markers of aerial parts. [P4]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P7]
- HPLC for flavonol glycoside markers of aerial parts (quercetin 3-O-robinobioside-7-O-glucoside, quercetin 3-O-rutinoside-7-O-glucoside, kaempferol 3-O-robinobioside-7-O-glucoside) — BAPP: these markers reveal undeclared leaf or aerial-part extract in root extracts; withanolide patterns alone are unreliable because several chemotypes exist. [P4]
- Microscopy of crude powder; HPTLC or HPLC identity and withanolide quantification — BAPP: pharmacopeial standards (USP, British, Indian and Ayurvedic pharmacopoeias, WHO) cover microscopic, HPTLC and HPLC identification of the root; stems and leaves in crude powder can be identified microscopically. [P4]
Supply and conservation
- Cultivated: BAPP (2018) reports about 10,770 hectares of ashwagandha grown in India with annual production of 8,429 metric tons, including more than 5,000 hectares in the Neemuch and Mandsaur districts of Madhya Pradesh. [P4]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada, Ashwagandha monograph (February 28, 2025), adults 18 and older: 2-6 g dried root per day (traditional Ayurvedic claims); 2.5-6.5 g dried root or whole plant per day (adaptogen claim). [P5]
Sources for this profile
- NCCIH. Ashwagandha: Usefulness and Safety (Last Updated: 2023-03), 2023-03. nccih.nih.gov
- NIH Office of Dietary Supplements. Ashwagandha: Health Professional Fact Sheet (Updated May 2, 2025), 2025-05-02. ods.od.nih.gov
- NIH LiverTox (NIDDK). Ashwagandha (Last Update: December 3, 2024), 2024-12-03. ncbi.nlm.nih.gov
- Singh VK, Mundkinajeddu D, Agarwal A, Nguyen J, Sudberg S, Gafner S, Blumenthal M. Adulteration of ashwagandha (Withania somnifera) roots and extracts. Botanical Adulterants Prevention Bulletin. ABC-AHP-NCNPR Botanical Adulterants Prevention Program; 2018 (PDF dated January 2019), 2019-01. umb.herbalgram.org
- Health Canada, NNHPD. Monograph: Ashwagandha - Withania somnifera (dated February 28, 2025), 2025-02-28. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- IARC Monographs. List of Classifications (retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list retrieved October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
Sources
- NCCIH. Ashwagandha: Usefulness and Safety (Last Updated: 2023-03), 2023-03. nccih.nih.gov
- NIH Office of Dietary Supplements. Ashwagandha: Is it helpful for stress, anxiety, or sleep? Health Professional Fact Sheet (Updated May 2, 2025), 2025-05-02. ods.od.nih.gov
- NIH LiverTox (NIDDK). Ashwagandha (Last Update: 2024-12-03), 2024-12-03. ncbi.nlm.nih.gov
- Akhgarjand C, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2022;36(11):4115-4124 (PMID 36017529), 2022-08-25. pubmed.ncbi.nlm.nih.gov
- Cheah KL, et al. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One 2021;16(9):e0257843 (PMID 34559859), 2021-09-24. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.